Clinical Trial Update: Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver [Phase 3]

View source ↗

Summary

Phase 3 trial of satavaptan to prevent recurrence of ascites in patients with cirrhosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ascites
• Liver Cirrhosis

Drugs mentioned

• Satavaptan (satavaptan)

Snippet

Sponsor: Sanofi | Conditions: Ascites, Liver Cirrhosis | Phase 3 | Status: TERMINATED